FULC
$7.43
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage produ...
Recent News
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk
Fulcrum Therapeutics (NASDAQ:FULC) executives highlighted what they described as strong physician interest and encouraging clinical signals from the company’s PIONEER study in sickle cell disease during a recent discussion hosted by Leerink Partners equity research analyst Joe Schwartz. PIONEER tak
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel
Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF may comfortably be greater than 20% given the strength of the initial cut at ASH, the firm thinks “overly nitpicking 19.3% is splitting hairs and misses the bigger picture” as these data surpassed the physician “bar” and that pociredir is reaching HbF levels expected to be highly protective of diseas
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Fulcrum Therapeutics, Inc.'s Q4 2025 earnings call
Fulcrum Therapeutics Q4 Earnings Call Highlights
Fulcrum Therapeutics (NASDAQ:FULC) shared full 12-week results from the 20-mg cohort of its phase 1b PIONEER trial evaluating pociredir in patients with sickle cell disease, expanding on partial data previously presented at the American Society of Hematology (ASH) meeting in December 2025. Managemen
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
The consensus price target hints at a 75.7% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.